The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / EULAR 2012: Remission the New Normal for Rheumatoid Arthritis

EULAR 2012: Remission the New Normal for Rheumatoid Arthritis

August 8, 2012 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF

His larger question, though, was whether biologics perform better than synthetic disease-modifying agents.

You Might Also Like
  • EULAR 2014: Research on Rheumatoid Arthritis, Spondyloarthritis
  • Drug Updates: EULAR 2012
  • California Rheumatology Alliance 2013 Meeting: Aim for Remission in Rheumatoid Arthritis
Explore This Issue
August 2012
Also By This Author
  • EULAR 2013: Researchers Make Inroads in Treatment of Osteoarthritis

In the IDEA study, patients were randomized to receive methotrexate plus the anti–tumor necrosis factor (TNF) drug infliximab (Remicade) or methotrexate plus IV methylprednisolone. After 26 weeks in both arms, if DAS 28 scores were 2.4 or lower, the therapy was continued at current doses; if higher, it was escalated.8 The study found that the two arms performed similarly.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Treat to target is effective in early disease—rapid and sustained remission can be achieved by both ways, but obviously this [the nonbiologic approach] is the more affordable way,” said Dr. Smolen. But he also noted that 15% of patients, whose disease activity remained high after 26 weeks, were switched from nonbiologic therapy to biologic, and benefited.

In the SWEFOT trial, patients were started on methotrexate and, if they still had moderate to high disease activity after three months, were switched to either conventional triple therapy (sulfasalazine, hydroxychloroquine, and methotrexate) or infliximab.9 There were advantages in the infliximab arm after a year, but after two years, “these differences were not apparent,” Dr. Smolen said. “Neither clinical nor radiologic.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The results aren’t easily interpreted, he said. One take-home message might be that traditional therapy can yield similar results to infliximab if it is sustained long enough. On the other hand, Dr. Smolen said, 24 of 130 patients had to withdraw from the conventional arm because of lack of efficacy, while just 5 of 128 dropped out from the biologic arm due to lack of efficacy.

Dr. Smolen called the TEAR study “one of the most complex clinical trials he’s seen in recent years—or ever.” The study started with two pairs of arms. The first pair included a conventional triple-therapy arm and a methotrexate-plus-etanercept arm. The second pair included subjects who all started on methotrexate then, if their disease activity was moderate to high, were switched to either standard triple therapy or etanercept.

Those in the etanercept arms collectively were more likely to have profound effects, with a higher percentage of ACR70 response rates and better radiographic outcomes, but the overall performance was similar in both the biologic and nonbiologic arms. Dr. Smolen also had doubts about the power of this study, because the dropout rate was much higher than anticipated.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Smolen said a major question among rheumatologists is how biologics compare.

In the AMPLE trial, immunomodulator abatacept plus methotrexate was compared with TNF-inhibitor adalimumab plus methotrexate in patients with active disease, and there was overall a very close similarity in this analysis.10

Pages: 1 2 3 4 5 | Single Page

Filed Under: Biologics & Biosimilars, Conditions, Drug Updates, Guidelines, Meeting Reports, Rheumatoid Arthritis Tagged With: Biologics, EULAR, HYDROXYCHLOROQUINE, infliximab, International, Methotrexate, patient care, Rheumatoid arthritis, rheumatologist, tocilizumabIssue: August 2012

You Might Also Like:
  • EULAR 2014: Research on Rheumatoid Arthritis, Spondyloarthritis
  • Drug Updates: EULAR 2012
  • California Rheumatology Alliance 2013 Meeting: Aim for Remission in Rheumatoid Arthritis
  • EULAR 2012: Rewards in Risk Factor Research

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.